Skip to main navigation Skip to search Skip to main content

Reduced antibody cross-reactivity following infection with b.1.1.7 than with parental sars-cov-2 strains

  • Crick COVID-19 Consortium
  • , SAFER Investigators

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Background: The degree of heterotypic immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains is a major determinant of the spread of emerging variants and the success of vaccination campaigns, but remains incompletely understood. Methods: We examined the immunogenicity of SARS-CoV-2 variant B.1.1.7 (Alpha) that arose in the United Kingdom and spread globally. We determined titres of spike glycoprotein-binding antibodies and authentic virus neutralising antibodies induced by B.1.1.7 infection to infer homotypic and heterotypic immunity. Results: Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa variant B.1.351 (Beta) than of the infecting variant. The drop in cross-reactivity was significantly more pronounced following B.1.1.7 than parental strain infection. Conclusions: The results indicate that heterotypic immunity induced by SARS-CoV-2 variants is asymmetric.

Original languageEnglish
JournaleLife
Volume10
DOIs
StatePublished - Jul 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021, eLife Sciences Publications Ltd. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Reduced antibody cross-reactivity following infection with b.1.1.7 than with parental sars-cov-2 strains'. Together they form a unique fingerprint.

Cite this